The global vocal biomarkers market is anticipated to grow at a CAGR of 14.5% during the forecast period (2021-2027). The market growth is mainly attributed to the rising adoption of minimally invasive procedures for diagnosis, and advancements in technology by major players across the globe. Minimally invasive eventually assist the patients to get rid of pain, cuts, and any type of risk associated with any clinical instrument. Moreover, these instruments are accurate with high speed and cost-effective too. These features can drive the growth of the market in the forecast period. Such advancement in technologies includes capturing our subtle changes in voice including pitch, intensity, pauses, and much more for determining our health conditions within a fraction of time. Market players are involved in working on tools of voice data to detect a wide range of diseases. For Instance, in October 2020, Mayo Clinic collaborated with Vocalis Health for the clinical development of new voice-based tools for detecting and monitoring patient’s health.
A full report of Vocal Biomarkers Market is available at: https://www.omrglobal.com/industry-reports/vocal-biomarkers-market
In July 2021, PureTech Health plc, a clinical-stage biotherapeutics company, announced that its subsidiary, Sonde Health, will work with Qualcomm Technologies, Inc. to optimise the use of Sonde’s vocal biomarker technology on the Qualcomm Snapdragon 888 and 778G 5G Mobile Platforms to assist bring native, machine learning-driven vocal biomarker capabilities to mobile and IoT devices globally. The optimization has the potential to enable various native health screening and monitoring applications on the hundreds of millions of mobile devices that employ these Snapdragon mobile platforms.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/vocal-biomarkers-market
In November 2019, Sonde Health, Inc. a company developing a voice-based technology platform to monitor health when a person speaks, has announced that the US Patent and Trademark Office issued U.S. Patent No. 10,475,530, a foundational patent that covers important features of Sonde’s vocal biomarker technology. The patent includes Sonde’s method for capturing, analysing, and utilising vocal biomarkers to enable more efficient and prompt disease detection and treatment. People with diseases ranging from depression to dementia to allergies may be able to seek care more rapidly if disease diagnosis and treatment decisions are improved in this way. Thus, the market players contribution in the development of vocal biomarkers is to drive the market growth during the forecast period.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Application
o By End-User
o By Type
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Vocalis Health, Inc., IBM Corp., Sonde Health, Inc., Boston Technology Corp, Medical Information Technology, Inc, and Orbita Inc., among others
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Vocal Biomarker Market Report Segment
By Application
- Psychological Disorders
- Neurological Disorders
- Respiratory Disorders
- Cardiovascular Disease
By End-User
- Hospitals
- Diagnostic Centre
- Academics Research Institute
By Type
- Frequency
- Amplitude
- Error Rate
- Vocal Rise or Fall Time
- Phonation Time
- Voice Tremor
- Pitch
- Others
This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.
